Catch and controlled release

Controlled-release formulations are becoming increasingly popular
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
As companies look for new ways to extend their current drug portfolios and as an aging population looks for easier ways to take their medications, controlled-release formulations are becoming increasingly popular.
 
According to a January report by Kalorama Information, the drug delivery technology sector accounted for more than $3 billion of the overall oral drug delivery market's $35 billion in 2006 with the controlled/sustained- and delayed-release segments being responsible for the lion's share. According to report author and Kalorama analyst Mary Anne Crandall, growth in this market continues to be fueled by the introduction of many line extensions in both the controlled-release and fast-dissolving product segments.
 
"Pharmaceutical companies are increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products as they approach or succumb to patent loss," she said in a statement announcing the report. "At the same time, other concerns, such as finding convenient forms and market acceptance of new biopharmaceuticals, and tapping into the growing elderly population that requires products with a level of ease-of-use and cost benefit, will continue to stimulate the market for oral delivery."
 
For its part, U.K.-based Critical Pharmaceuticals is looking at both the oral delivery market as well as other drug delivery markets as it develops its supercritical fluid technology for drugs and delivery vehicles.
 
"These could be formulated into controlled-released products with a range of possible morphologies, including microparticles, fibers and implants," says Dr. Andrew Naylor, the company's process development project manager. "A range of other morphologies can be produced for potential applications including mucosal delivery—e.g., via the lung—drug-eluting wound dressings, drug-eluting stents and anti-abuse formulations."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue